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Synaptic dysfunction is the best anatomical correlate of early cognitive impairment in Alzheimer’s dis-
ease (AD). Electroencephalography (EEG) directly reﬂects brain electrical activity at the level of synapses.
The aim of the present study was to investigate correlations of quantitative EEG measures, global ﬁeld
power (GFP) and global ﬁeld synchronization (GFS), with conventional cerebrospinal ﬂuid (CSF) bio-
markers of neurodegeneration in patients diagnosed with subjective cognitive decline (n ¼ 210), mild
cognitive impairment (n ¼ 230), and AD (n ¼ 197). Decreased CSF amyloid b42 signiﬁcantly correlated
with increased theta and delta GFP, whereas increased p- and t-tau with decreased alpha and beta GFP.
Decreased CSF amyloid b42 and increased p- and t-tau were signiﬁcantly associated with decreased GFS
alpha and beta. Subanalysis of the separate diagnostic groups demonstrated signiﬁcant correlations
between CSF biomarkers and generalized power and synchronization already in the subjective cognitive
decline and MCI group. These results provide evidence that quantitative EEG measures are associated
and possibly sensitive to distinct AD-like CSF biomarker proﬁles in cognitively impaired patients and are
therefore promising early noninvasive markers of AD.
 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The identiﬁcation and validation of reliable biomarkers of Alz-
heimer’s disease (AD) that reﬂect both preclinical and early clinical
stages of disease is a major research goal, considering it might
provide a crucial opportunity for an intervention with disease-
modifying drugs. Although AD diagnosis currently encompasses
clinical stages only, the time between the initial brain changes and
symptoms of clinically manifest disease is considered to represent
the pathological-clinical continuum of AD (Sperling et al., 2011).
According to Jessen et al., the prediction of dementia in AD supportsatrics, Department of Neuro-
itutet, Hälsovägen 7, 14157
8585470.
.
Inc. This is an open access article uthe model of AD continuum; that is, a transition from subjective
cognitive decline throughmild cognitive impairment (SCD andMCI,
respectively) to dementia (Jessen et al., 2010, 2014). Indeed, a
certain proportion of memory clinic referrals diagnosed with SCD
and MCI at the baseline exhibit biomarker abnormalities such as
decreased amyloid b42 (Ab42), increased total tau (t-tau) and
phospho tau (p-tau) protein levels in cerebrospinal ﬂuid (CSF)
(Blennow, 2004), increased amyloid burden as assessed by positron
emission tomography (PET) with Pittsburgh compound B (PiB-PET)
(Amariglio et al., 2012; Forsberg et al., 2008), brain atrophy detected
by magnetic resonance imaging (MRI), and decreased glucose
metabolism by ﬂuorodeoxyglucose PET (FDG-PET) (de Leon et al.,
2007). These subjects are at high risk of developing further cogni-
tive decline (Jessen et al., 2010, 2014).
Synaptic dysfunction in AD has recently gained increasing
attention, especially since there has been evidence that synapticnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2004) and is the best anatomical correlate of cognitive deﬁcits in
MCI and AD (Blennow et al., 1996; Goetzl et al., 2016; Scheff et al.,
2011; Terry et al., 1991). Moreover, synaptic dysfunction is an
early event in AD preceding cognitive decline and neuronal cell
death (de Wilde et al., 2016; Selkoe, 2002), resulting in greater
synapse loss compared with neuronal depletion in the same brain
regions (Heinonen et al., 1995; Masliah et al., 1991). Consequently,
given that biochemical and structural abnormalities appear later
(Selkoe, 2002; Sperling et al., 2011) and are already characterized by
reasonably valid and widespread CSF and imaging biomarkers in
both research and clinical use, there is an urgent need for methods
that mirror functional rather than just structural changes. Hypo-
metabolism and/or hypoperfusion in the temporoparietal regions,
assessed by functional imaging technologies, such as FDG-PET or
single-photon emission computed tomography (SPECT), have been
reported in patients with AD (Foster et al., 1984; Jagust et al., 1987).
However, referred imaging modalities provide indirect evidence of
synaptic dysfunction and neurodegeneration (Wicklund and
Petersen, 2013) whose sensitivity and speciﬁcity remain unclear
(Albert et al., 2017; Bhriain and Lawlor, 2002).
One of the ﬁrst measurements that directly reﬂects functioning
of synapses in real time was the electroencephalography (EEG)
consisting of scalp electric potential differences (Jelic, 2005; Michel,
2009). EEG offers several additional attractions: noninvasiveness,
wide availability, low cost, high time resolution, and direct access to
neuronal signaling in contrast to functional MRI or PET that detect
indirect metabolic signals (Michel, 2009). In research settings, the
most commonly used method is a computerized or quantitative
EEG (qEEG) analysis that disentangles EEG signal in frequency, time,
and space domain and gives information on connectivity and
topography of neuronal networks (Jelic, 2005; Jelic and Kowalski,
2009). It has been postulated that both synapse and neuronal loss
result in reduced brain functional connectivity and have an inﬂu-
ence on EEG signals (Jelic, 2005). Slowing of fast-frequency bands
(alpha and beta) and increase in slow-frequency bands (delta and
theta) activity assessed by qEEG have been repeatedly reported in
AD (Dierks et al., 1991; Jelic et al., 1996; Soininen et al., 1991).
However, conventional fast Fourier transformation spectral analysis
conducted in a vast number of qEEG analyses has a disadvantage of
resulting in many parameters and reference-dependent topo-
graphical interpretation. Such properties represent shortcomings of
conventional spectral power analysis when it comes to compre-
hensive correlative studies employing other biological measures.
Global ﬁeld power (GFP) is a reference-free method that reduces
multichannel recordings to a single measure corresponding to the
generalized EEG amplitude (Huang et al., 2000a; Jelic, 2005). Its
computation takes into account all electrodes uniformly and
therefore results in a global measure of scalp potential ﬁeld
strength (Michel, 2009). According to Huang et al., AD patients
show an increase of delta and theta GFP as well as a reduction of
alpha and beta GFP compared with the controls and MCI patients,
respectively (Huang et al., 2000a). GFP and dipole source localiza-
tion analysis in MCI, AD, and healthy controls showed a promising
diagnostic and prognostic classiﬁcation accuracy (Huang et al.,
2000a). On the other hand, AD has been characterized as a
“disconnection syndrome” as a result of neurodegeneration and
neuronal loss, which affects coherent ﬁring of corticocortical pro-
jections (Koenig et al., 2005; Morrison et al., 1996). In this context,
global ﬁeld synchronization (GFS) emerged as a novel qEEG mea-
sure of global functional connectivity of the brain. GFS as a single
measure results from the multichannel analysis that does notinvolve a priori selections and modeling of particular regions of
interest, which is along with the postulated hypothesis of func-
tional “disconnection syndrome” of broadly distributed neural
networks. It resembles global amount of instantaneous phase-
locked synchronization of oscillating neuronal networks across
the scalp (Koenig et al., 2001, 2005). Decreased GFS in fast-
frequency bands in a gradient-like pattern was indeed found in
SCD, MCI, and AD compared to controls, supporting the hypothesis
of early disruptions of brain functional connectivity in AD patho-
genesis (Koenig et al., 2005).
Very few explorative clinical studies have tried to address the
biological validity of qEEG measures and investigate their correla-
tion with conventional markers of neurodegeneration in patients
with different clinical stages of cognitive impairment. Only 1 study
so far explored the relationship of qEEG parameters and conven-
tional markers of neurodegeneration in patients with cognitive
decline but involved only a modest number of subjects (Jelic et al.,
1998).
The aim of the present studywas to investigate the correlation of
qEEG parameters GFP and GFS with conventional CSF biomarkers of
core ADmolecular pathology (Ab, t-tau, and p-tau) in a large cohort
of memory clinic patients with a wide range of cognitive
impairment.2. Subjects and methods
2.1. Study population
The study population consisted of 637 patients recruited at the
memory clinic at the Karolinska University Hospital Huddinge,
Stockholm, Sweden, (2007e2010 and 2013e2016) who underwent
standard comprehensive assessment consisting of a clinical inter-
view and examination, neuropsychological testing, screening blood
tests, CSF biomarkers analyses, brain imaging with computed to-
mography (CT) or MRI, and digital resting-state EEG recording. The
severity of cognitive deﬁcits was assessed using MinieMental State
Examination (MMSE) (Folstein et al., 1975). The patients were
clinically diagnosed with AD (n ¼ 197) according to ICD-10 (World
Health Organization, 1993), MCI (n ¼ 230) according to the criteria
of Winblad et al. (2004), and SCD (n ¼ 210) in case they reported
subjective complaints but had normal clinical investigationwithout
any signiﬁcant cognitive deﬁcit (Jessen et al., 2010). Patients with
other dementia diagnoses were excluded as well as those below
50 years of age, those with a time gap between baseline diagnosis
and EEG recording longer than 6 months, major neurological co-
morbidity, epilepsy, psychiatric disorder, alcohol abuse, and chronic
medication with any of the psychotropic drugs known to inﬂuence
EEG activity.2.2. Ethical approval
The study was approved by the local ethical committee of the
Karolinska University Hospital Huddinge. The patients gave their
written consent to register, store, and analyze clinical data and
correlate these to biochemical, genetic, and clinical examination
results for research purposes. The existing electronic database that
includes patients investigated at the memory clinic has been re-
ported to the Swedish Data Inspection Board and falls under the
legislation on personal Data Act and Act on Ethical Review on
research involving human subjects.
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The CSF was obtained by lumbar puncture between the L3/L4
or L4/L5 intervertebral space while the patient was sitting in an
upright position. All CSF withdrawals were performed in the
morning using a 25-gauge needle and collected in 12 mL
polypropylene tubes. CSF samples were centrifuged at 1000 rpm
for 10 minutes, divided into polypropylene tubes of 1 mL, and
frozen at 70 C until further analysis. Ab42, p-tau, and t-tau
concentrations were simultaneously measured with the xMAP
technology and the INNO-BIA AlzBio3 kit (Innogenetics), as
previously described in detail (Olsson et al., 2005). Variables
were transformed with zero-skewness logarithmic trans-
formation (using the natural logarithm) to obtain nonskewed
distributions.
2.4. EEG recordings
Resting-state EEGs were recorded on the Nervous System at the
Department of Clinical Neurophysiology, Karolinska University
Hospital-Huddinge. Electrodes were placed according to the stan-
dard 10/20 system with electrode impedances below 5 kU and a
sampling rate of 256 Hz. The patients were seated in a sound-
attenuated, normally lit room with their eyes closed. A technician
monitored the entire EEG recordings to alert the patient (using
acoustic stimulation) in case of drowsiness or sleep. Initial ﬁlter
settings were a time constant of 1 second and low-pass ﬁlter fre-
quency of 70 Hz. Digital EEG recordings were stored for further
analysis ofﬂine.
2.5. Quantitative EEG analysis
A minimum of 20-second eyes-closed artifact-free epochs
were selected after visual inspection and manual rejection of
artifacts, episodes of drowsiness, and eyes-open periods. Any
electroocular, electrocardiographic, and lateral eye-movement
artifacts were eliminated by semiautomatic independent
component analysis algorithm. Frequency analysis was per-
formed using the fast Fourier transformation and Brain Vision
Analyzer, version 2.0, software. Epochs of 2-second duration,
which allowed a resolution of 0.5 Hz in the frequency spectrum,
were averaged. GFP is a measure of global strength of scalp po-
tential ﬁelds deﬁned as the root mean of all squared potential
differences between all electrode pairs. It therefore corresponds
to the standard deviation of the potentials (Lehmann andTable 1
Descriptive statistics and CSF biomarker values according to the diagnostic group
SCD
Number 210
Sex ratio (males/females) 79/131
Age, y 60.0  6.1 (50e83)
Education, y 13.3  3.6 (1e24.5)
MMSEa 28.7  1.7 (23e30)
CSF biomarkers
CSF Ab42 (ng/L) 916.90  248.85 (300e1650)b,c
CSF p-tau (ng/L) 52.41  21.52 (16e183)b,c
CSF t-tau (ng/L) 256.35  121.37 (43e689)b,c
ANOVA over the diagnostic groups; p < 0.001 for all CSF biomarkers. Games-Howell tes
Key: AD, Alzheimer’s disease; ANOVA, analysis of variance; CSF, cerebrospinal ﬂuid; MCI,
cognitive decline.
a n ¼ 627 (SCD ¼ 206, MCI ¼ 228, and AD ¼ 193).
b p < 0.01, SCD versus MCI.
c p < 0.01, SCD versus AD.
d p < 0.01, MCI versus AD.Skrandies, 1980; Michel, 2009). GFS was computed for each fre-
quency bin using a principal component analysis of the 2-
dimensional positions of the electrode entries in the sine-
cosine diagram. The normalized difference between the result-
ing 2 Eigenvalues of the ﬁrst and second principal components
(per frequency) is a measure of cloud spread and corresponds to
GFS. Its values range from 0 to 1 and represent the percentage of
EEG activity that can be attributed to sources oscillating with a
common phase at a given frequency; high GFS values assume
predominance of single phase over all electrodes, whereas low
GFS values indicate the absence of such a common phase (Koenig
et al., 2001). GFP and GFS were averaged across epochs and
within the conventional frequency bands: delta (1e3.5 Hz), theta
(4e7.5 Hz), alpha (8e11.5 Hz), and beta (12e19.5 Hz). Obtained
GFP values were transformed with zero-skewness logarithmic
transformation to get nonskewed distributions for further sta-
tistical analysis.2.6. Statistical analysis
Simple descriptive statistics in SPSS (IBM SPSS Statistics,
version 23.0) software was used to present the distribution of
the subjects in diagnostic groups, demographic characteristics
(gender, age, and years of education), MMSE, and CSF biomarker
values of the study population. The differences between GFS
and logarithmically transformed GFP and CSF values across
diagnostic groups were investigated by a 1-way analysis of
variance (ANOVA). Games-Howell post hoc tests for unequal
variance (Levene’s test p < 0.05) were performed, where sig-
niﬁcant group effects between CSF values were found. A mul-
tiple linear regression analysis of the whole study sample was
performed in statistical software STATA, using GFP and GFS in
conventional frequency bands as dependent and CSF values as
independent continuous variables while controlling for age,
gender, and MMSE. Subsequent statistical analysis of the 3
separate diagnostic groups was performed using linear regres-
sion model with the same independent and dependent vari-
ables, controlled for age and gender only. Beta coefﬁcients
indicate in which direction (positive or negative) and how much
a dependent variable varies with an independent variable,
when all other independent variables are held constant. The
analysis was separately performed for each CSF (Ab42, t-tau,
and p-tau), GFP, and GFS frequency band measures. The level of
signiﬁcance was set at 5%.MCI AD
230 197
109/121 72/125
65.9  8.2 (50e87) 67.8  9.2 (51e89)
12.1  3.8 (3e22) 11.1  3.6 (6e23)
27.3  2.1 (18e30) 23.0  4.3 (7e30)
713.63  271.69 (229e1532)b,d 500.90  123.55 (250e876)c,d
62.73  28.60 (16e175)b,d 91.49  37.57 (16e240)c,d
363.59  210.32 (41e1140)b,d 628.70  309.54 (103e1500)c,d
t for post hoc comparisons. Results are presented as means  standard deviation.
mild cognitive impairment; MMSE, MinieMental State Examination; SCD, subjective
Fig. 1. Box plot of GFP (y-axis) in different frequency bands (x-axis). The box repre-
sents the interquartile range; the solid line within the box marks the median; and the
upper and lower whiskers represent the upper and lower 25% of the distribution,
respectively. Diagnostic groups are represented by different bar patterns. ANOVA over
the diagnostic groups; *p < 0.05. Abbreviations: ANOVA, analysis of variance; GFP,
global ﬁeld power.
Table 3
Relationship between CSF biomarkers and GFP across the diagnostic groups
CSF biomarker Frequency band SCD MCI AD
Ab42 GFP delta 0.010 0.351a 0.329
GFP theta 0.095 0.449a 0.465
GFP alpha 0.329 0.176 0.136
GFP beta 0.149 0.002 0.226
p-tau GFP delta 0.026 0.143 0.438b
GFP theta 0.006 0.311 0.404
GFP alpha 0.364 0.626c 0.311
GFP beta 0.150 0.320b 0.305a
t-tau GFP delta 0.046 0.060 0.239a
GFP theta 0.104 0.151 0.147
GFP alpha 0.317 0.337b 0.130
GFP beta 0.161 0.162a 0.198a
Multiple linear regression analysis controlled for age and gender. Data presented as
b coefﬁcients. The dependent variables are zero-skewness logarithmically trans-
formed GFP in different frequency bands, whereas independent variables are zero-
skewness logarithmically transformed CSF biomarker values. This means that the b
coefﬁcients just indicate in which direction (positive or negative) and how strong
the associations are.
Key: AD, Alzheimer’s disease; CSF, cerebrospinal ﬂuid; GFP, global ﬁeld power; MCI,
mild cognitive impairment; SCD, subjective cognitive decline.
a p < 0.05.
b p < 0.01.
c p < 0.001.
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3.1. Demographics
Demographic data, MMSE scores, and CSF biomarker values of
the study cohort are presented in Table 1. There is a shift toward
younger patient population because the memory clinic at the Kar-
olinska Hospital Huddinge is a referral center for subjects under
65 years of age in the Stockholm municipality. The mean age was
higher in the AD group followed by the MCI group; the ratio of
female compared with male patients was similar in all diagnostic
groups. The mean MMSE score was 1.4 points and 5.7 points lower
in MCI and AD, respectively, compared with the SCD group. There
was a signiﬁcant difference between all CSF biomarker levels across
diagnostic groups (ANOVA/Games-Howell p < 0.01). The cutoff
values for the conventional CSF markers were Ab42 > 550 ng/L,
p-tau < 80 ng/L, and t-tau < 400 ng/L.3.2. Association between GFP and CSF biomarkers
The GFP means and 95% conﬁdence intervals (CIs) in conven-
tional frequency bands across diagnostic groups are shown in Fig. 1.
There were statistically signiﬁcant differences in GFP between
diagnostic groups as determined by 1-way ANOVA in delta (p ¼
0.003), theta (p < 0.001), and alpha (p ¼ 0.026) frequency band.Table 2
Relationship between CSF biomarkers and GFP in 4 frequency bands
CSF biomarker GFP delta GFP theta GFP alpha GFP beta
Ab42 0.304a 0.514b 0.170 0.002
p-tau 0.107 0.076 0.409b 0.278b
t-tau 0.048 0.011 0.222a 0.175b
Multiple linear regression analysis controlled for age, gender, and MMSE. Data
presented as b coefﬁcients. The dependent variables are zero-skewness logarith-
mically transformed GFP in different frequency bands, whereas independent vari-
ables are zero-skewness logarithmically transformed CSF biomarker values. This
means that the b coefﬁcients just indicate in which direction (positive or negative)
and how strong the associations are.
Key: CSF, cerebrospinal ﬂuid; GFP, global ﬁeld power; MMSE, MinieMental State
Examination.
a p < 0.01.
b p < 0.001.A multiple linear regression model, controlling for age, gender,
and MMSE, showed a signiﬁcant negative association of CSF Ab42
and GFP in the delta (p ¼ 0.001) and theta (p < 0.001) frequency
band, that is, lower Ab levels were associated with higher delta and
theta power (Table 2.). Separate linear regression analyses for the 3
diagnostic groups showed signiﬁcant negative correlations
between CSF Ab42 and GFP delta and theta in the MCI group
(p ¼ 0.016 and p ¼ 0.025, respectively) (Table 3).
Multiple regression analysis revealed a similar association of
CSF p- and t-tau levels with power in fast-frequency bands;
higher p-tau and t-tau signiﬁcantly correlated with decrease of
GFP in alpha (p-tau: p < 0.001; t-tau: p ¼ 0.003) and beta fre-
quency bands (p-tau: p < 0.001; t-tau: p < 0.001) (Table 2.).
Statistical analysis for the 3 groups separately showed a signiﬁ-
cant inverse association between p- and t-tau and GFP alpha (p-
tau: p < 0.001; t-tau: p ¼ 0.005) and beta (p-tau: p ¼ 0.005; t-
tau: p ¼ 0.04) in the MCI group and GFP delta (p-tau: p ¼ 0.008;
t-tau: p ¼ 0.04) and beta (p-tau: p ¼ 0.013; t-tau: p ¼ 0.022) in
the AD group (Table 3).Fig. 2. Box plot of GFS (y-axis) in different frequency bands (x-axis). The box repre-
sents the interquartile range; the solid line within the box marks the median; and the
upper and lower whiskers represent the upper and lower 25% of the distribution,
respectively. Diagnostic groups are represented by different bar patterns. ANOVA over
the diagnostic groups; *p < 0.05. Abbreviations: ANOVA, analysis of variance; GFS,
global ﬁeld synchronization.
Table 4
Relationship between CSF biomarkers and GFS in 4 frequency bands
CSF biomarker GFS delta GFS theta GFS alpha GFS beta
Ab42 0.002 0.001 0.024b 0.013b
p-tau 0.002 0.001 0.015b 0.005
t-tau 0.001 0.001 0.010b 0.004a
Multiple linear regression analysis controlled for age, gender, and MMSE. Data
presented as b coefﬁcients. The dependent variables are GFS in different frequency
bands, whereas independent variables are zero-skewness logarithmically trans-
formed CSF biomarker values. The b coefﬁcients indicate in which direction (positive
or negative) and how strong the associations are.
Key: CSF, cerebrospinal ﬂuid; GFS, global ﬁeld synchronization; MMSE,
MinieMental State Examination.
a p < 0.05.
b p < 0.001.
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The GFS means and 95% CI in conventional frequency bands
across diagnostic groups are shown in Fig. 2. Therewere statistically
signiﬁcant differences in GFS between group means as determined
by 1-way ANOVA in the delta (p ¼ 0.012), alpha (p < 0.001), and
beta (p < 0.001) frequency bands.
Multiple linear regression, controlling for age, gender, and
MMSE, showed a signiﬁcant positive correlation between CSF Ab42
and GFS alpha (p< 0.001) and beta (p< 0.001), that is, lower CSFAb
values were associated with lower fast-frequency GFS (Table 4). The
following separate analyses of the diagnostic groups revealed a
signiﬁcant direct correlation between CSF Ab42 and GFS alpha
(p ¼ 0.002) and beta (p ¼ 0.034) in the MCI group and GFS alpha
(p < 0.001) in the AD group (Table 5).
CSF p-tau and t-tau exhibited signiﬁcant negative correlation
with GFS alpha (p-tau: p < 0.001; t-tau: p < 0.001) and beta (t-tau
only; p ¼ 0.017), that is, increase in p- and t-tau levels was associ-
ated with decreased GFS in fast-frequency bands (Table 4). The
multiple regression analysis for the groups revealed a negative
association between CSF p- and t-tau and GFS alpha in the MCI (p-
tau: p < 0.001; t-tau: p < 0.001) and GFS beta in the SCD group (p-
tau only; p ¼ 0.012) (Table 5).Table 5
Relationship between CSF biomarkers and global ﬁeld synchronization between
diagnostic groups
CSF biomarker Frequency band SCD MCI AD
Ab42 GFS delta 0.002 0.002 0.000
GFS theta 0.009 0.003 0.012
GFS alpha 0.016 0.022b 0.045c
GFS beta 0.009 0.010a 0.009
p-tau GFS delta 0.001 0.002 0.006
GFS theta 0.002 0.003 0.002
GFS alpha 0.014 0.023c 0.000
GFS beta 0.013a 0.002 0.001
t-tau GFS delta 0.002 0.000 0.003
GFS theta 0.000 0.004 0.001
GFS alpha 0.008 0.015c 0.002
GFS beta 0.006 0.003 0.001
Multiple linear regression analysis controlled for age and gender. Data presented as
b coefﬁcients. The dependent variables are GFS in different frequency bands,
whereas independent variables are zero-skewness logarithmically transformed CSF
biomarker values. The b coefﬁcients indicate in which direction (positive or nega-
tive) and how strong the associations are.
Key: AD, Alzheimer’s disease; CSF, cerebrospinal ﬂuid; GFS, global ﬁeld synchroni-
zation; MCI, mild cognitive impairment; SCD, subjective cognitive decline.
a p < 0.05.
b p < 0.01.
c p < 0.001.4. Discussion
This study is unique with respect to the large population of
memory clinic patients being investigated with a comprehensive
assessment battery including EEG and spinal taps, which are rarely
performed routinely in patients without clinical evidence of de-
mentia or objective cognitive impairment. The most important
ﬁnding is the correlation of general EEG slowing and reduced
synchronizationwith lower CSFAb42 and higher p- and t-tau levels.
To our knowledge, no studies so far have reported the association
between different, yet complementary, qEEG measures of gener-
alized power and global functional connectivity and AD-associated
CSF markers of neurodegeneration in a large patient cohort with
wide spectra of cognitive impairment.
Similar changes in the pattern of EEG power spectra have been
repeatedly reported in AD; namely an early increase in theta and
decrease in beta, a subsequent decrease in alpha and a late increase
in delta band power, resulting in general EEG slowing (Coben et al.,
1985; Dierks et al., 1991). A previous study conducted in the same
memory clinic cohort presented a correlation of lower CSF Ab42/p-
tau ratio and higher t-tau with slower background activity and a
higher degree of episodic EEG abnormalities (Kramberger et al.,
2013), based on visual analysis only. Although these results are
consistent with our ﬁndings in the context of general slowing of
EEG activity, visual assessment includes interobserver variations
that should be taken into consideration. Stomrud et al. investigated
the relationship between qEEG frequency analysis and conven-
tional CSF biomarkers obtained in 33 subjects over 4 years. They
reported a strong association of p-tau/Ab42 and t-tau/Ab42 with an
increase of relative theta power and slowing of cognitive speed but
included healthy elderly individuals only (Stomrud et al., 2010). Our
ﬁndings provide evidence that lower CSF Ab42 and higher p- and t-
tau values correlated with increased EEG slowing in the entire
memory clinic cohort. We have excluded the effect of signiﬁcant
group differences in qEEGmeasures by controlling for MMSE values
in the correlative analyses of the whole study population. There-
fore, our results support referred ﬁndings irrespective of the
severity of cognitive deﬁcit such as group diagnosis.
Moreover, relationships among CSF markers of AD neuropa-
thology and EEG frequencies displayed distinct patterns, with Ab42
exhibiting signiﬁcant association with global power in slow (delta
and theta) while p- and t-tau in fast (alpha and beta) frequencies
only. These discrepancies may be explained by sensitivity of spec-
tral EEG activity toward different neuropathological changes.
The widely accepted explanation for the reduction in CSF Ab42
found in AD patients is that aggregation and retention of Ab into
plaques lead to reduced diffusion of Ab into the CSF (Motter et al.,
1995). One of the studies aiming to investigate the role of amy-
loid accumulation in aging and dementia included subjects with
Down’s syndrome (DS) who overexpress amyloid precursor pro-
teins due to 21-trisomy (Tanzi et al., 1987). According to their re-
sults, both DS and AD patients had increased delta and theta power
compared with controls, but DS had preserved alpha and beta po-
wer as opposed to AD (Soininen et al., 1993).
One of the possible mechanisms underlying the observed rela-
tionship between Ab42 and increased slow EEG activity might be
the relation of Ab and cholinergic deﬁcits in the AD brain. Previous
studies have demonstrated that Ab disrupts muscarinic signaling
(Huang et al., 2000b; Kelly et al., 1996) and negatively affects
acetylcholine synthesis and release (Hoshi et al., 1997; Kar et al.,
1998; Vaucher et al., 2001). Concurrently, decrease in cortical
cholinergic activity is associated with increase of slow EEG activity
(Riekkinen et al., 1990; Spehlmann and Norcross, 1982). Thus, the
negative effect of Ab on cholinergic transmission in the brain could
indirectly cause increase in slow-frequency activity.
U. Smailovic et al. / Neurobiology of Aging 63 (2018) 88e95 93On the contrary, our results indicate that CSF p- and t-tau pro-
tein levels were selectively associated with EEG fast frequencies.
Previous studies have demonstrated that both CSF p- and t-tau
presumably indicate the extent of neuronal damage and degener-
ation since they inversely correlate with gray matter density in
temporal, parietal, and frontal lobes (Thomann et al., 2009) and
hippocampal volume (Herukka et al., 2008) and predict whole-
brain and regional atrophy in cognitively impaired and AD pa-
tients (Tarawneh et al., 2015). Meanwhile, qEEG studies have shown
that alpha amplitude negatively correlated with the hippocampal
atrophy and cortical gray matter in the MCI and AD subjects
(Babiloni et al., 2009, 2013, 2015). Although thalamic neuronal
networks possibly contribute to the production of fast rhythms, it
has been postulated that alpha and beta are predominantly
generated in the cortex itself and propagated through intracortical
connections (da Silva, 2009). We suggest that EEG activity, specif-
ically fast rhythms, are somewhat associated with neuronal loss
evidenced by brain atrophy and increased CSF tau protein levels.
Overall, qEEG parameters that have plausible sensitivity toward
different neuropathological changes in the AD brain could serve as a
noninvasive method for distinguishing patients with isolated am-
yloid pathology from amyloid-negative primary age-related tauo-
pathies (Crary et al., 2014).
On the other hand, hypothesis of early disruption in brain
functional connectivity in AD patients suggests that a measure of
global brain functional connectivity could be used as a supportive
marker of early AD: A previous study based on computerized qEEG
analysis demonstrated that global synchronization correlated with
MMSE and Clinical Dementia Rating scales of cognitive impairment
in AD patients (Park et al., 2008). Our results show that lower CSF
Ab42 and higher t-tau levels correlated with decreased global
synchronization in alpha and beta, whereas higher p-tau with
decreased synchronization in alpha band only. This is in line with
previous reports that decrease of alpha and beta synchronization
mirrors particular neuropathological changes, such as neuronal
loss, synaptic dysfunction, degeneration of associative ﬁbers, and
possibly cholinergic dysfunction, and has a speciﬁc signiﬁcance in
AD (Koenig et al., 2005; Stam et al., 2003). In addition, the impor-
tance of high-frequency synchronization for cognition has recently
been emphasized because different studies reported most pro-
nounced correlations between global synchronization and degree
of cognitive decline in alpha and beta bands (Koenig et al., 2005; Ma
et al., 2014; Park et al., 2008; Stam et al., 2003).
The following subanalyses of separate diagnostic groups
demonstrated correlations of qEEG global power with AD-like CSF
biomarker changes in MCI and AD patients, whereas with global
EEG synchronization such correlation was present already in the
SCD group. These signiﬁcant associations across different fre-
quencies were particularly abundant in the MCI group. It has been
proposed that AD biomarker abnormalities obtain sigmoid-shaped
courses over time and reach a “plateau” by the time of the clinically
developed dementia (Sperling et al., 2011). The steep part of the
referred dynamic curve, associated with MCI, represents the high-
est rate of the biomarker changes, which might explain the robust
relationship between CSF and qEEG markers in this predementia
stage of the disease. Both analyses seem to yield less prominent
relationships in the AD group, possibly due to the referred “plateau
effect”, that is, rather constant CSFAb42, p-tau, and t-tau levels over
time in patients with dementia (Le Bastard et al., 2013). Interest-
ingly, CSF p- and t-tau levels inversely correlated with GFP delta in
the AD group only, implying less pronounced EEG slowing once the
critical level of neurodegeneration and neuronal loss has been
reached.
Our ﬁndings support the hypothesis that qEEG measures of
global power and synchronization are potential surrogate markersof early AD because they signiﬁcantly correlate with AD-like CSF
biomarker abnormalities already in the SCD and MCI group of pa-
tients. It has been postulated that combinations of conventional CSF
biomarker abnormalities characteristic of AD are predictive of
future dementia development in MCI patients (Hansson et al.,
2006; Visser et al., 2009). In addition, global power and dipole
source localization analysis in MCI, AD, and healthy controls
showed a promising diagnostic and prognostic classiﬁcation accu-
racy (Huang et al., 2000a). Thus, the observed correlations
restricted to our cross-sectional study indicate that qEEG parame-
ters have a prognostic potential that should be further explored
through longitudinal studies including both healthy and cognitively
impaired individuals. Another limitation of this study was lack of a
healthy control group because of the constraint in obtaining CSF
from healthy individuals and use of global, nonlocal qEEGmeasures
only. It would be of great relevance to extend this study and include
alternative neuroimaging modalities of synaptic dysfunction and
other neuropathological hallmarks of AD. MRI and PET topo-
graphical markers have been shown consistently to predict the
development of AD dementia in MCI cohorts (Aguilar et al., 2014;
Morris et al., 2009) and to correlate with disease severity (Jack
et al., 2002; Nordberg et al., 2010). In this context, interpretation
of EEG scalp ﬁeld and source topographies and employment of
novel measures of brain functional connectivity would yield valu-
able add-on to such correlative studies.
In conclusion, our study demonstrates plausible correlation of
qEEG power and synchronization with AD proﬁles of CSF abnor-
malities in a large memory clinic cohort along different stages of
cognitive impairment, making them promising noninvasive
markers of synaptic dysfunction due to neurodegeneration.
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